A French Technology Transfer Office offers a novel anti-cancer chemical compound
A French Technology Transfer Office (TTO) offers a novel chemical compound with anti-proliferative and vascular inhibition properties validated in vitro and in vivo. It is a new class of chemical agents with a strong anti-cancer activity for the treatment of solid tumors, in particular in the colon, lung, ovaries and uterus. The French TTO is looking for technological partners for a license agreement, technical cooperation agreement or a research cooperation agreement.
The partner sought could be a large corporate, medium-sized company or startup operating in pharmaceutical, drug design or biotechnology development. These companies are focused in order to set up a licensing agreement, or a technical cooperation agreement in case of further needed development to meet industrial and clinical challenges. The partner sought could be also a university in order to launch a research cooperation agreement with the French laboratory.
The French Technology Transfer Office (TTO) is acting on behalf of an established public laboratory of a university of the Paris region. The present offer proposes a novel chemical compound with non-proliferative and vascular inhibition properties validated in vitro and in vivo. It is a class of chemical agents targeting tubulin polymerization with a high hydrophilic structure and a strong anti-cancer activity. This compound has shown highly efficient anti-cancer potency in vitro models using 24 cancer cell lines (some of them being resistant to chemotherapies). In vivo, after intra-peritoneal injection, this compound has shown a tumor volume reduction of 80-95% on lung and colon murine tumors with no major identified side effects. After intra-peritoneal injection, the pharmacokinetic profile in mice is good with a half-life of 91mn and a bioavailability of 47%. There is a need for new anticancer agents associated with increased response rates and with limited and manageable toxicity. This treats solid tumors, in particular in the lungs which is the most common cause of cancer-related death in men and the second most common in women; in the colon which is the third most common type of cancer for all groups; in the ovaries which is the seventh-most common cancer for woman; and also in the uterus. Keywords : Anti-proliferative, anti-vascular, anti-cancer, treatment, solid tumors, cancer, lung cancer, colon cancer, ovaries cancer, uterus cancer, tubulin polymerization, Tumor Therapy The partner sought could be a university, a SME or a large company interested in a license agreement or a research cooperation agreement or a technical cooperation agreement. The French TTO is able to provide technical and legal assistance to facilitate the eventual partnership. In case of business potential, the prototype can be partially funded by the TTO.
Advantages and innovations
The advantages of this technology are: - water soluble - stable and easy to synthetize - high efficiency in a powerful in vitro colon 26 cell lines - better efficacy than the anti-vascular comparator combretastatin CA4.
Available for demonstration
Intellectual Property Rights (IPR)
Register your interest
How it works
- Tell us about yourself
- We’ll discuss with you
- We put the right partners in touch
EEN help you find the right partner, rather than you going it alone.
Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.
These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.
Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.
First we need to check you’re human.
Thank you for verifying your email. We have sent you a confirmation email containing a 6 digit verification code to unlock the form below